Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.110
-0.170 (-13.28%)
Nov 16, 2026, 4:00 PM EST - Market closed
Cabaletta Bio Employees
As of March 31, 2026, Cabaletta Bio had 158 total employees, including 156 full-time and 2 part-time employees. The number of employees decreased by 9 or 5.39% compared to the same quarter last year. That makes Cabaletta Bio the 28,473rd largest employer in the world and 3,582nd in the United States.
Employees
158
Change (1Y)
-9
Growth (1Y)
-5.39%
Revenue / Employee
n/a
Profits / Employee
-$1,199,399
Market Cap
239.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 158 | -9 | -5.39% | 156 | 2 |
| Dec 31, 2025 | 156 | -8 | -4.88% | 154 | 2 |
| Sep 30, 2025 | 151 | -4 | -2.58% | 148 | 3 |
| Jun 30, 2025 | 170 | 32 | 23.19% | 167 | 3 |
| Mar 31, 2025 | 167 | 47 | 39.17% | 163 | 4 |
| Dec 31, 2024 | 164 | 61 | 59.22% | 161 | 3 |
| Sep 30, 2024 | 155 | 61 | 64.89% | 154 | 1 |
| Jun 30, 2024 | 138 | 59 | 74.68% | 136 | 2 |
| Mar 31, 2024 | 120 | 53 | 79.10% | 118 | 2 |
| Dec 31, 2023 | 103 | 43 | 71.67% | 101 | 2 |
| Sep 30, 2023 | 94 | 35 | 59.32% | 92 | 2 |
| Jun 30, 2023 | 79 | 21 | 36.21% | 77 | 2 |
| Mar 31, 2023 | 67 | 10 | 17.54% | 66 | 1 |
| Dec 31, 2022 | 60 | 6 | 11.11% | 58 | 2 |
| Sep 30, 2022 | 59 | 12 | 25.53% | 57 | 2 |
| Jun 30, 2022 | 58 | 19 | 48.72% | 57 | 1 |
| Mar 31, 2022 | 57 | 21 | 58.33% | 56 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Bicycle Therapeutics | 288 |
| Protalix BioTherapeutics | 226 |
| Rocket Pharmaceuticals | 202 |
| Inovio Pharmaceuticals | 112 |
| Arcturus Therapeutics Holdings | 111 |
| Immuneering | 65 |
| Camp4 Therapeutics | 48 |
CABA News
- 6 days ago - Cabaletta Bio Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 7 days ago - Cabaletta Bio price target lowered to $8 from $10 at Citi - TheFly
- 8 days ago - Cabaletta Bio announces new Phase 1/2 data on rese-cel at ACR Convergence 2026 - TheFly
- 8 days ago - Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases - GlobeNewsWire
- 8 days ago - Cabaletta Bio Slides: Corporate presentation - Filings
- 11 days ago - Cabaletta Bio expects myositis topline results in second half of 2027 - TheFly
- 11 days ago - Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Cabaletta Bio Quarterly report: Q3 2026 - Filings